NexgenRx Announces Annual Meeting Results

TORONTO, ON / ACCESSWIRE / June 10, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was held on Thursday, June 10, 2021. The Meeting was held, in part, to deliver the annual financial statements and related management's discussion and analysis of the Company, fix and appoint the directors of the Company, appoint the Company's auditors and approve the Company's Stock Option Plan, all as more particularly set out in the Management Information Circular that was delivered to shareholders in advance of the Meeting.

At the Meeting, all resolutions were passed by the shareholders of the Company. A total of 42,234,076 common shares were represented at the Meeting either in person or by proxy, representing approximately 60.046% of the issued and outstanding shares of the Company.

Due to continuing public health concerns related to the COVID-19 pandemic and in order to comply with the measures imposed by the federal and provincial governments, shareholders were strongly encouraged not to attend the Meeting in person and to submit their proxies in accordance with the instructions provided in advance of the Meeting. A "listen only" dial-in phone number was provided for shareholders to listen to the proceedings; however the Company has been made aware that some shareholders had technical difficulties and were not able to listen to the proceedings. The Company has therefore posted a recording of the Meeting on its website, which can be accessed at the following link: http://en.nexgenrx.com/company/background. As the Meeting was properly constituted and a quorum was satisfied, the technical problems experienced by some shareholders had no bearing on the results of the Meeting, since the dial-in facility was for listening only (and was not set up to allow for either voting, nor discussion).

The Company also announces that Ms. Christa Plumley is stepping down from her role as Corporate Secretary of the Company. Tom Corcoran, Chairman of the Board of directors, commented "It has been a pleasure working with Christa and, on behalf of the Board, we express our sincere thanks to her for her 10 years of service as Corporate Secretary of the Company. Not only has she fulfilled her role in an exemplary fashion, but has often made significant contributions to board discussions." The role of Corporate Secretary will now be assumed by Mr. Paul Bolger of Tingle Merrett LLP. Mr. Bolger has served as the Company's corporate legal counsel since 2006, when the Company completed its IPO and listing on the TSX Venture Exchange.

About NexgenRx
NexgenRx is Canada's only independent full-service Third-Party Administrator and Technology Solutions Provider, offering proprietary full front-end, eligibility, enrolment, hour bank and mobile access capabilities, together with state-of-the-art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide Plan Sponsors, sophisticated administration and health benefit technology applications in a cost-effective SaaS (Software As a Service) Model.

NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for existing and new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; continued development and enhancement of the Company's proprietary software technology; cyber security risks and the other risks and uncertainties disclosed in our annual Management's Discussion and Analysis, as filed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

FOR FURTHER INFORMATION PLEASE CONTACT:
Ronald C. Loucks
NexgenRx Inc.
President and CEO
416.695.3393 x801

Kelly Ehler CPA, CA
NexgenRx Inc.
Chief Financial Officer
416-695-3393x803

SOURCE: NexgenRx Inc.